Live
- NSCN-IM warns of 'horrible human rights situation' if Naga political talks fail
- Let BJP win, save the nation: BJP MP candidate Potuganti Bharat Prasad
- NDA will win over 130 seats in Andhra Pradesh: Jyothsna
- Basketball league, INBL Pro, to be played with six teams over August, September
- Sex video scandal: K’taka HM asks NCW to share information on threats to victim
- Back among his supporters, Kejriwal says 140 cr people have to fight against dictatorship
- BJP will win in Nagar Kurnool: BJP state spokesperson Dileep
- In Matua-dominated Ranaghat, Amit Shah slams Trinamool for opposing CAA
- Sam Pitroda row: Congress trying to convey that India is not united, says Pralhad Joshi
- Cyber frauds: DoT directs telecom providers to block 28,200 mobiles, reverify 20 lakh connections
Generic glaucoma drug to halt myopia progression
A generic glaucoma drug has been shown to halt the progression of myopia (nearsightedness), potentially offering rapid approval for a new treatment of an incurable condition. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md. Scientists induced myopia in guinea pig eyes then treated the eyes wit
A generic glaucoma drug has been shown to halt the progression of myopia (nearsightedness), potentially offering rapid approval for a new treatment of an incurable condition. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md. Scientists induced myopia in guinea pig eyes then treated the eyes with artificial tears or topical latanoprost, a drug that is commonly used to treat glaucoma. Lantanoprost significantly slowed myopia progression over three months. Myopia is expected to affect half of the world’s population by 2050. Though correctable through glasses, it is known to lead to blinding conditions including cataracts, glaucoma and retinal detachments. Getting regulatory approval to use existing drugs for new conditions is often years faster than creating a new drug.
